26.40
+0.43(+1.66%)
Currency In USD
| Previous Close | 25.97 |
| Open | 26.06 |
| Day High | 26.65 |
| Day Low | 25.66 |
| 52-Week High | 42.27 |
| 52-Week Low | 6.43 |
| Volume | 316,304 |
| Average Volume | 384,126 |
| Market Cap | 963.54M |
| PE | -11.63 |
| EPS | -2.27 |
| Moving Average 50 Days | 28.15 |
| Moving Average 200 Days | 19.42 |
| Change | 0.43 |
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline
GlobeNewswire Inc.
Jan 07, 2026 12:00 PM GMT
U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarter of 2026 On strength of RAP-219 Phase 2a FOS dat
Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 18, 2025 12:00 PM GMT
BOSTON and SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
GlobeNewswire Inc.
Dec 05, 2025 2:00 PM GMT
Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with consistent efficacy data regardless of patients’ disease severity RAP-219 demonstrated meaningful